Chester County News and Community Website
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) to …
FDA Grants Priority Review to J&J sBLA for IMAAVY in wAIHA Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) recently reported new Phase 3 data showing sustained symptom improvement and reduced antibody levels in patients with generalized myasthenia gravis treated with …
Johnson & Johnson Reports Long-Term Data on Myasthenia Drug Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced recently that its oral psoriasis treatment ICOTYDE (icotrokinra) achieved sustained skin clearance rates through 52 weeks in Phase 3 clinical …
Johnson & Johnson Reports Psoriasis Drug Results From Phase 3 Studies Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and …
FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults …
FDA Approves TECVAYLI and DARZALEX FASPRO Combo for Multiple Myeloma Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of IMAAVY (nipocalimab-aahu) …
Johnson & Johnson Submits FDA Application for IMAAVY in wAIHA Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), to …
Johnson & Johnson Receives FDA Approval for Monthly RYBREVANT FASPRO Dosing Read More
PHILADELPHIA, PA — A jury in the Philadelphia Court of Common Pleas awarded $250,000 against Johnson & Johnson (NYSE: JNJ), finding the company’s talc-based baby powder products contributed to the …
Philadelphia Jury Awards $250,000 in J&J Talc Cancer Trial Read More
What This Means for You More than 500 new jobs are expected in Montgomery County over the next 12 years. The state will provide up to $41.5 million in financial …
Johnson & Johnson to Invest $1 Billion in Montgomery County Cancer Drug Facility Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More